Negative
●
Invezz
●
about one month ago
US-listed shares of Novo Nordisk fell more than 6% on Tuesday after the Danish drugmaker released its second-quarter financial results and updated its full-year outlook a day ahead of its scheduled earnings announcement, with investors focusing on softer-than-expected sales of its oral Wegovy weight-loss drug. Novo Nordisk's American depositary receipts declined despite the company narrowing th...